SMALL DUCT CHOLANGITIS INDUCED BY N-FORMYL L-METHIONINE L-LEUCINE L-TYROSINE IN RATS

被引:44
作者
YAMADA, S [1 ]
ISHII, M [1 ]
LIANG, LS [1 ]
YAMAMOTO, T [1 ]
TOYOTA, T [1 ]
机构
[1] TOHOKU UNIV,SCH MED,DEPT INTERNAL MED 3,1-1 SEIRYO MACHI,AOBA KU,SENDAI,MIYAGI 980,JAPAN
关键词
SMALL DUCT CHOLANGITIS; COLITIS; BACTERIA-DERIVED PEPTIDE;
D O I
10.1007/BF02365447
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Primary sclerosing cholangitis (PSC) frequently accompanies inflammatory bowel diseases. In an attempt to increase our understanding of the pathogenesis of PSC, we studied bile duct changes in rats with colitis which had been given N-formyl L-methionine L-leucine L-tyrosine (fMLT) rectally; fMLT is one of the chemotactic peptides produced by Escherichia coli, and is secreted into the bile by hepatocytes after it enters the portal blood. Transrectal administration of fMLT induced a marked inflammation in the portal triad and mild hepatocyte necrosis on the 4th day. The infiltrating leukocytes in the portal tract were mostly mononuclear cells, which densely infiltrated around the bile ducts. These mononuclear cells appeared to attach to bile duct epithelial cells, and they were more numerous in the smaller bile ducts. Electron microscopy revealed that lymphocytes were in direct contact with bile duct lining cells and that some epithelial cells had degenerated or collapsed. These results suggest that this E. coli-derived peptide may induce cholangitis in the small bile duct through cell-mediated mechanisms. Since these pathologic changes resemble those of the bile duct observed in the early stage of PSC, it can be concluded that bacterial chemotactic peptides may play a role in the pathogenesis of small-duct PSC.
引用
收藏
页码:631 / 636
页数:6
相关论文
共 21 条
[1]  
Wiesner R.H., LaRusso N.F., Clinicopathologic features of the syndrome of primary sclerosing cholangitis, Gastroenterology, 79, pp. 200-206, (1980)
[2]  
Adaland E., Schrumpf E., Fausa O., Et al., Primariy sclerosing cholangitis: A long-term follow-up study, Scandinavian Journal of Gastroenterology, 22, pp. 655-664, (1987)
[3]  
Ludwig J., Barham S.S., LaRusso N.F., Et al., Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis, Hepatology, 1, pp. 632-640, (1981)
[4]  
Wee A., Ludwig J., Pericholangitis in chronic ulcerative colitis: Primary sclerosing cholangits of small bile ducts?, Ann Intern Med, 102, pp. 581-587, (1985)
[5]  
Brooke B.N., Dyke P.W., Walker F.C., A study of liver disorder in ulcerative colitis, Postgraduate Medical Journal, 37, pp. 245-251, (1961)
[6]  
Kono K., Ohnishi K., Omata M., Et al., Experimental portal fibrosis produced by intraportal injection of killed nonpathogenic Escherichia coli in rabbit, Gastroenterology, 94, pp. 787-796, (1988)
[7]  
Hobson C.H., Butt T.J., Ferry D.M., Et al., Enterohepatic circulation of bacterial chemotactic peptide in rats with experimental colitis, Gastroenterology, 94, pp. 1006-1013, (1988)
[8]  
Lichtman S.N., Sartor R.B., Keku J., Et al., Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth, Gastroenterology, 98, pp. 414-423, (1990)
[9]  
Lefkowitch J.H., Primary sclerosing cholangitis, Arch Intern Med, 142, pp. 1157-1160, (1982)
[10]  
Ludwig J., Small-duct primary sclerosing cholangitis, Semin Liver Dis, 11, pp. 11-17, (1991)